Druck Icon

Eckert & Ziegler: 11% Profit Growth in the 9-Month Period

Berlin, November 02, 2011. The first nine months of 2011 developed extraordinarily successful for the Eckert & Ziegler Group (ISIN DE0005659700), a specialist for isotope applications in medicine, science and industry. The revenue of EUR 83.6 million and the profit after taxes and minorities of EUR 8.8 million mean new record results for the period of time January to September. Compared with the corresponding period of the previous year the revenue increased by EUR 2.6 million or 3% and the profit by EUR 0.9 million or 11%. The earnings per share in the 9-month period are EUR 1.68 per share.

The key figures for the third quarter of 2011 alone are also pleasing, even if in the direct comparison with the same quarter of the previous year a slight fall in revenue can be recorded from 1% to EUR 27.8 million and with the profit from 20% to EUR 2.2 million. There are several reasons for this fall and it is partly due to the exchange rates and the development in interest rates. In addition, the revenue and income of the previous year from the Russia project from the Radiation Therapy segment are missing in 2011. Seen in purely operative terms no negative trend can be determined in the development of business.

The Isotope Products segment accounts for the greatest share of the total results. The revenue rose by 6% here. All product categories recorded growth with the exception of the Medical segment. In the ratio to the revenue the costs only increased less than proportionate owing to economies of scale. Thus, EBIT could be increased by 16%.

The Radiopharma segment recorded the strongest growth. Increases were also achieved here in all product lines. In total the segment increased the revenue by 20% to EUR 19.1 million. As the segment partly profits from very low marginal costs for the production and sales a large part of the growth in revenue is reflected in the profits.

The Radiation Therapy segment (previously: Therapy) could not as expected achieve the record revenue of the previous year. Profits were realised from the plant sale to Russia in the comparable period of the previous year. Comparable are therefore only the figures within the year 2011. The revenue increased slightly compared with the previous quarter. The EBIT with EUR 0.6 million is less than the directly preceding quarter as the development costs have increased. Detailed statements relating to the Radiation Therapy segment can be taken from the quarterly report of Eckert & Ziegler BEBIG S.A. (previously: IBt S.A.), which is published at the same time (www.bebig.eu).

The revenue with external customers is constant compared with the previous year in the Environmental Services segment. As however orders are also placed within the Group and moreover costs were saved there are no losses suffered any more as opposed to the previous year.

For the fiscal year 2011 the revenue target is EUR 110 to 120 million. The Board of Directors reinforces its profit forecast of EUR 2.00 per share (results after taxes and minorities >EUR 10 million). By the end of 2014 the board of directors is expecting a profitable increase in sales to around EUR 200 million per year.

With around 580 employees the Eckert & Ziegler Group belongs to the largest providers of isotope components for radiation therapy and nuclear medicine worldwide.

If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com